HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium

The HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium, funded by the Bill & Melinda Gates Foundation combines expertise in policy, access, introduction, implementation, and evaluation and learning to accelerate uptake of HPV vaccines globally.The consortium aims to increase and sustain equity, program quality, and accelerate coverage of HPV vaccination among girls and adolescents to contribute to the Gavi, the Vaccine Alliance (Gavi), goal of 86 million girls and adolescents vaccinated by 2025 and the global goal of 90% coverage by 2030. 

Additionally, the work of this consortium will support the Bill & Melinda Gates Foundation’s goal of vaccinating another 37 million girls above and beyond Gavi’s goal of 86 million. HAPPI partners seek to achieve this through: 

• Targeted technical assistance to countries for accelerated HPV vaccine introduction and coverage improvement
• Targeted learning, measurement, and evaluation of existing programs and pilots 
• Translation of lessons learned into policy, guidelines, and practices
• Extend and complement global coordination of the core HPV vaccine partners

The HAPPI consortium will run through December 2026. The consortium is managed by JSI together with Clinton Health Access Initiative (CHAI), the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, Jhpiego, and PATH as partners.

Photo: © Gates Archive/Ricci Shryock. Noura Mariam Konate after receiving the HPV vaccine in Abidjan, Ivory Coast on April 26, 2023